An analysis of the recent investment activity in antibody–drug conjugates (ADCs) prior to Pfizer's (NYSE: PFE) newly-announced $43 billion takeover of Seagen (Nasdaq: SGEN).
An ADC is typically composed of a monoclonal antibody (MAb) covalently attached to a cytotoxic drug (payload) via a chemical linker (which helps to increase tumor specificity and reduce off-target effects. In 2021, the ADC market was worth $4 billion and is forecast to rise to $13.13 billion by 2030, delivering a CAGR 2021-2030 of 14.12% (Figure 1).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze